Inactive Instrument

Analyst Reco. Global Blood Therapeutics, Inc.

Equities

GBT

US37890U1088

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	22-08-09	MT
SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target	22-08-09	MT
Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66	22-08-09	MT
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adjusts Price Target to $68.50 From $75	22-08-09	MT
William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-09	MT
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67	22-08-09	MT
Guggenheim Downgrades Global Blood Therapeutics to Neutral From Buy, Sets $68.50 Price Target	22-08-08	MT
Oppenheimer Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-08	MT
Wedbush Downgrades Global Blood Therapeutics to Neutral From Outperform on Pfizer Acquisition, Lowers PT to $68.50 From $74	22-08-08	MT
Stifel Nicolaus Downgrades Global Blood Therapeutics to Hold From Buy, Adjusts Price Target to $68.50 From $65	22-08-08	MT
Truist Securities Downgrades Global Blood Therapeutics to Hold From Buy, Adjusts Price Target to $68.50 From $50	22-08-08	MT
Jefferies & Co. Downgrades Global Blood Therapeutics to Hold From Buy, Adjusts Price Target to $68.50 From $68	22-08-08	MT
Canaccord Genuity Upgrades Global Blood Therapeutics to Buy From Hold, Adjusts Price Target to $72 From $40	22-08-08	MT
RBC Cuts Price Target on Global Blood Therapeutics to $60 From $63, Maintains Outperform Rating	22-07-07	MT
JPMorgan Lowers Global Blood Therapeutics' Price Target to $36 From $39, Maintains Neutral Rating	22-06-28	MT
Wedbush Lifts Price Target on Global Blood Therapeutics to $74 From $73 on Oxbryta Estimates, Keeps Outperform Rating	22-06-13	MT
HC Wainwright Adjusts Global Blood Therapeutics' Price Target to $65 from $75, Keeps Buy Rating	22-05-05	MT
Oppenheimer Adjusts Global Blood Therapeutics Price Target to $71 From $86, Maintains Outperform Rating	22-05-05	MT
Wedbush Lifts Price Target on Global Blood Therapeutics to $73 From $71, Keeps Outperform Rating	22-05-05	MT
RBC Capital Adjusts Global Blood Therapeutics' Price Target to $63 From $65, Maintains Outperform Rating	22-04-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Global Blood Therapeutics, Inc.

Equities

GBT

US37890U1088

Analyst Reco.

Filters